medicine journal updates

2. There was no significant difference between
clindamycin and tmp-smx with respect to
either efficacy or side effect profile in both
children and adults.
NEJM-MARCH,19,2015

3. Canagliflozin when added to insulin therapy
improved glycemic control and decreased
body weight
S.E: genital mycotic infections, uti
diabetes care , 2015

4.  DIFFERENCE >10 mmhg IN INTER ARM
BLOOD PRESSURE LINKED TO GREATER
RISK OF FUTURE CARDIOVASCULAR
EVENTS.
AMERICAN JOURNAL OF MEDICINE,MARCH

5. Streptococcus pneumoniae is the most
common pathogen in patients with
AECOPD.
Piperacillin +Tazobactum should be the first
choice empirical antibiotic.
Quinolones are less effective
journal of pulmonary and respiratory medicine, january
26,2015

6.  Pirfenidone reduces the rate of annual
FVC decline in patients with IPF.
 Pirfenidone has well-established anti
fibrotic and anti inflammatory properties
 downregulates the production of growth
factors and procollagens I and II.

7. Almost 4 out of 5 MI in men may be
preventable with a combined low risk
behaviour.
JACC,FEBRUARY,17,2015.

8. Low risk behaviour :
1.Healthy diet
2.Moderate alcohol consumption 10-
30g/day
3.No smoking
4.Being physically active,walking
/bicycling>=40mins/day and exercising>=1
hour/week
5.No abdominal adiposity(waist
circumference <95 cm.)

9.  Approved for treatment of chronic heart failure.
 Indicated to reduce the risk of hospitalization for worsening
heart failure in patients with :
Stable , symptomatic chronic heart failure with lvef <=35%,
who are in sinus rhythm with resting heart rate >=70 beats /
minute and either on maximal tolerated dose of beta blockers
or in whom beta blocker is contrindicated
FDA approval, APRIL,2015.

10.  Inhibits if channels
 Recommended dosage: 5 mg b.d
2 weeks
7.5 mg b.d

11. Crohns disease
High levels of SMAD 7
Reduced levels of TGF –BETA
( immuno suppressive cytokine)
NEJM-MARCH,19,2015

12.  Pentoxyfylline did not improve survival in patients
with alcoholic hepatitis
 Prednisolone was associated with a reduction in 28
day mortality that did not reach significance and no
improvement in outcomes at 90 days or 1 year
NEJM, APRIL 23, 2015

13. This new molecule is named LCZ-696,is a combination
of ARB and neprilysin inhibitor
Neprilysin is a zinc-dependent metalloprotease that
cleaves peptides at the amino side of hydrophobic
residues and inactivates several peptide hormones
JACC MARCH 2015